With bioinformatic and experimental approaches, we have demonstrated that medium‐dose formoterol treatment attenuated EPO‐induced AAA mainly by targeting VSMC senescence via β2AR/cAMP/SIRT1 signals (Figure 9). This evidence concerns the gene ADRB2 and triple-A syndrome.